Johnson & Johnson (JNJ) Stock Profile & Financial OverviewJohnson & Johnson
JNJ Company Overview & Business Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Key Information
Current Trend for JNJ
An assessment of the current trend environment for JNJ, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for JNJ is an Indeterminate Transition Phase (Unclear Direction).
Daily and weekly trends are conflicting, reducing directional conviction and making directional trading less favorable at this stage.
- The weekly backdrop provides strong tailwinds, confirming that the medium-term path of least resistance is upward.
- Price is currently compressing tightly (optimal low-risk zone), sitting 0.25 ATR away from the adaptive KAMA baseline.
- The market is maintaining a healthy 'Higher-High, Higher-Low' sequence, confirming buyer control.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, JNJ in a non-directional consolidation; Long-term trend is bullish.
Trend Strength: JNJ last closed at 207.78, trading 0.4 ATR above the adaptive KAMA baseline (206.31). Technical Classification: Non-Directional / Range-Bound.
Trend Score: Technical Score: 35/100. Classification: Sideways. Alignment: Indeterminate. Logic: Price action is range-bound or lacking sufficient slope for trend confirmation.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 194.08. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Non-Directional. Price is oscillating within a low-momentum range. Risk is two-sided, favoring mean-reversion strategies over trend-following.
Key Levels: Key technical references: Spot 207.78, KAMA 206.31.